Among the small molecules that inhibit exportin-1 function, selinexor (KPT-330) is under clinical trials for most cancer types, including leukemia, and lung, prostate, gastric, breast, ovarian, and cervical cancers [32]. This evidence concerns the gene XPO1 and cervical carcinoma.